Annual ROE
-222.33%
+40.05%+15.26%
31 December 2023
Summary:
Silence Therapeutics annual return on equity is currently -222.33%, with the most recent change of +40.05% (+15.26%) on 31 December 2023. During the last 3 years, it has fallen by -12.21% (-5.81%). SLN annual ROE is now -7213.49% below its all-time high of -3.04%, reached on 31 December 2017.SLN ROE Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly ROE
-79.63%
-9.74%-13.94%
01 September 2024
Summary:
Silence Therapeutics quarterly return on equity is currently -79.63%, with the most recent change of -9.74% (-13.94%) on 01 September 2024. Over the past year, it has increased by +128.19% (+61.68%). SLN quarterly ROE is now -108.46% below its all-time high of -38.20%, reached on 30 September 2020.SLN Quarterly ROE Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SLN ROE Performance
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
---|---|---|
1 y1 year | +15.3% | +61.7% |
3 y3 years | -5.8% | +64.7% |
5 y5 years | -421.4% | - |
SLN ROE High & Low
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
---|---|---|---|---|---|
3 y | 3 years | -5.8% | +51.1% | -13.9% | +79.8% |
5 y | 5 years | -421.4% | +51.1% | -108.5% | +79.8% |
alltime | all time | -7213.5% | +51.1% | -108.5% | +79.8% |
Silence Therapeutics ROE History
Date | Annual | Quarterly |
---|---|---|
Sept 2024 | - | -79.63%(+13.9%) |
June 2024 | - | -69.89%(-23.8%) |
Mar 2024 | - | -91.69%(-62.9%) |
Dec 2023 | -222.33%(-15.3%) | -247.01%(+18.9%) |
Sept 2023 | - | -207.82%(-20.9%) |
June 2023 | - | -262.75%(-14.2%) |
Mar 2023 | - | -306.11%(-6.9%) |
Dec 2022 | -262.38%(-42.3%) | -328.80%(+0.7%) |
Sept 2022 | - | -326.36%(-17.1%) |
June 2022 | - | -393.53%(+24.5%) |
Mar 2022 | - | -315.99%(+31.1%) |
Dec 2021 | -454.60%(+116.4%) | -241.02%(+6.8%) |
Sept 2021 | - | -225.57%(+13.5%) |
June 2021 | - | -198.69%(+15.8%) |
Mar 2021 | - | -171.54%(+41.2%) |
Dec 2020 | -210.12%(+202.1%) | -121.45%(+217.9%) |
Sept 2020 | - | -38.20% |
Dec 2019 | -69.55%(+63.1%) | - |
Dec 2018 | -42.64%(+1302.6%) | - |
Dec 2017 | -3.04%(-79.2%) | - |
Dec 2016 | -14.65%(-4.2%) | - |
Date | Annual | Quarterly |
---|---|---|
Dec 2015 | -15.30%(-62.9%) | - |
Dec 2014 | -41.22%(+4.6%) | - |
Dec 2013 | -39.39%(-64.2%) | - |
Dec 2012 | -110.15%(+495.1%) | - |
Dec 2011 | -18.51%(-56.2%) | - |
Dec 2010 | -42.25%(-38.5%) | - |
Dec 2009 | -68.70%(+36.9%) | - |
Dec 2008 | -50.19%(+61.7%) | - |
Dec 2007 | -31.04%(+27.1%) | - |
Dec 2006 | -24.43%(-41.0%) | - |
Dec 2005 | -41.44%(-47.4%) | - |
Dec 2004 | -78.71%(+124.8%) | - |
Dec 2003 | -35.02%(+96.3%) | - |
Dec 2002 | -17.84%(-16.6%) | - |
Dec 2001 | -21.38%(+14.2%) | - |
Dec 2000 | -18.72%(-44.8%) | - |
Dec 1999 | -33.93%(-14.4%) | - |
Dec 1998 | -39.64%(+5.5%) | - |
Dec 1997 | -37.59%(+170.8%) | - |
Dec 1996 | -13.88%(-56.9%) | - |
Dec 1995 | -32.21% | - |
FAQ
- What is Silence Therapeutics annual return on equity?
- What is the all time high annual ROE for Silence Therapeutics?
- What is Silence Therapeutics annual ROE year-on-year change?
- What is Silence Therapeutics quarterly return on equity?
- What is the all time high quarterly ROE for Silence Therapeutics?
- What is Silence Therapeutics quarterly ROE year-on-year change?
What is Silence Therapeutics annual return on equity?
The current annual ROE of SLN is -222.33%
What is the all time high annual ROE for Silence Therapeutics?
Silence Therapeutics all-time high annual return on equity is -3.04%
What is Silence Therapeutics annual ROE year-on-year change?
Over the past year, SLN annual return on equity has changed by +40.05% (+15.26%)
What is Silence Therapeutics quarterly return on equity?
The current quarterly ROE of SLN is -79.63%
What is the all time high quarterly ROE for Silence Therapeutics?
Silence Therapeutics all-time high quarterly return on equity is -38.20%
What is Silence Therapeutics quarterly ROE year-on-year change?
Over the past year, SLN quarterly return on equity has changed by +128.19% (+61.68%)